ESR1 and breast cancer: Among these subtypes is the triple-positive breast cancer (TPBC) subtype, which is immunohistochemically expressed as ER+/PR+/HER2+ and any Ki-67 status and accounts for approximately 10% of all breast cancer cases (2).